Geulah Livshits
Stock Analyst at Chardan Capital
(0)
# 3441
Out of 5,270 analysts
192
Total ratings
25.47%
Success rate
0.20%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Iovance Biotherapeut... | Maintains: Buy | 34 30 | 4.03 | 644.42% | 11 | Mar 3, 2025 | |
Prime Medicine | Maintains: Buy | 15 15 | 2.23 | 572.65% | 3 | Mar 3, 2025 | |
Rocket Pharmaceutica... | Maintains: Buy | 62 54 | 8.81 | 512.94% | 15 | Feb 28, 2025 | |
Intellia Therapeutic... | Maintains: Buy | 91 68 | 9.45 | 619.58% | 13 | Feb 28, 2025 | |
Taysha Gene Therapie... | Maintains: Buy | 7 7 | 1.6 | 337.5% | 12 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 212 218 | 171.51 | 27.11% | 9 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 15 16 | 5.13 | 211.89% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 94 84 | 42.26 | 98.77% | 12 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 30 | 4.16 | 621.15% | 7 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 13 13 | 1.48 | 778.38% | 9 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 18 | 0.95 | 1794.74% | 9 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 10 12 | 2.87 | 318.12% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 15 | 1.85 | 710.81% | 5 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 7 | 0.48 | 1358.33% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 23 25 | 2.37 | 954.85% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 17 11 | 0.61 | 1703.28% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 11 6 | 1.39 | 331.65% | 5 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 41 41 | 6.42 | 538.63% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 25 | 4.2 | 495.24% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 1.68 | 614.29% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 30 25 | n/a | n/a | 4 | Mar 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 191 208 | 30.27 | 587.15% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 160 40 | n/a | n/a | 3 | Dec 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 16 | 1.22 | 1211.48% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | 7.53 | -66.8% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 450 270 | n/a | n/a | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 90 | 5.93 | 1417.71% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 4 | 3.9 | 2.56% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | n/a | n/a | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 660 600 | 0.77 | 77822.08% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 50 30 | 4.16 | 621.15% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 18 | 8.91 | 102.02% | 1 | Oct 27, 2020 |